AstraZeneca Plots Crucial IDO Phase III Combo Trial With Incyte Post author:Sam Post published:October 30, 2017 Post category:BioPharma Astra and Incyte are pushing forward on the development of immunotherapy combination treatments. Source: BioSpace You Might Also Like 3 Biotechs That Could be Sweet M&A Targets for Big Pharma July 5, 2017 Beleaguered Axovant Begins Cutting Jobs While Exiting CEO Gets $2.6M+ Severance Package February 14, 2018 Sanofi's Rumored Buyout Target Flexion Shows Off Mid-Stage Osteoarthritis Data June 11, 2017
Beleaguered Axovant Begins Cutting Jobs While Exiting CEO Gets $2.6M+ Severance Package February 14, 2018